Optogenetic therapy, based on Nobel prize-winning science, involves turning nerve cells on and off using light ...
Andelyn Biosciences ("Andelyn"), a leading US-based patient-focused cell and gene therapy Contract Development and ...
September 30, 2026, 10:01 to October 7, 2026, 10:01 (JST)This week, progress was made in preparing for U.S. regulatory ...
The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma ...
The US FDA has approved Ultragenyx Pharmaceutical’s rebisufligene etisparvovec (Fayuvi) for paediatric patients with ...
Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization ...
CRISPR is one of this generation’s most profound innovations, with the potential to fundamentally alter the realm of modern ...
At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with ...
Successful production of reference protein advances proprietary protein engineering and gene therapy development ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. BOSTON — A medicine increasingly used to ...
Realizing the potential of cell and gene therapies will require organizations to rethink how they finance care and build the ...
Prioritize North America, cell therapy manufacturing and viral vectors; leverage AI, CRISPR, partnerships and scalable production to accelerate commercializationDublin, Oct. 07, 2026 (GLOBE NEWSWIRE) ...